Read more

August 04, 2023
1 min read
Save

Top in allergy/asthma: Early peanut introduction; asthma risk in teens on contraceptives

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Guidelines from the National Institute of Allergy and Infectious Diseases recommends introducing peanut into the diets of high-risk infants between age 4 and 6 months.

Yet, just 13.3% of parents and caregivers were aware of these guidelines, according to a study published in Pediatrics. It was the top story in allergy/asthma last week.

Peanuts and Peanut Butter
Just 13.3% of parents and caregivers were aware of guidelines on early peanut introduction, according to a study published in Pediatrics. Image source: Adobe Stock

The second top story was about girls’ risk for developing asthma after beginning hormonal contraceptive treatment before age 18 years. Researchers reported that the cumulative risk for new asthma was 2.7% after 3 years of beginning hormonal contraceptives.

Read these and more top stories in allergy/asthma below:

13.3% of caregivers aware of guidelines for early peanut introduction

The percentage of parents and other caregivers who know they should introduce peanuts into their infants’ diets to prevent allergy is improving, but disparities between populations exist, according to a study published in Pediatrics. Read more.

Asthma development associated with hormonal contraceptive use during adolescence

Girls who began hormonal contraceptive treatment before age 18 years experienced greater risk for developing asthma than girls who did not, according to a study published in the Journal of Allergy and Clinical Immunology: In Practice. Read more.

VIDEO: Manage patient relationships by following the Golden Rule

Providers need to manage patient relationships to prevent poor outcomes for everyone, according to an Association of PAs in Allergy, Asthma and Immunology Annual Allergy, Asthma & Immunology CME Conference presentation. Watch video.

Biologics comparably effective in controlling eosinophilic severe asthma symptoms

Nucala (mepolizumab, GSK), Cinqair (reslizumab, Teva Pharmaceutical Industries Ltd.) and Dupixent (dupilumab; Sanofi, Regeneron) were equally effective in controlling symptoms among patients with eosinophilic severe asthma, according to a study published in Annals of Allergy, Asthma & Immunology. Read more.

Physician assistants, nurse practitioners evolve with asthma, allergy care

As asthma and allergy treatment evolves, physicians, physician assistants and nurse practitioners will work together to ensure effective care, according to Andrew Liu, MD, FAAAAI, of Children’s Hospital Colorado. Read more.